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Abstract Alemtuzumab is a humanised anti-CD52 mono-
clonal antibody approved for use in active, relapsing mul-
tiple sclerosis (MS). Administration results in a rapid de-
pletion of circulating lymphocytes with a subsequent ben-
eficial immune reconstitution. Early open-label experience
and recent clinical trials have demonstrated a dramatic
effect on relapse rates as well as a positive effect on ra-
diological disease outcomes and disability measures.
Despite a mechanism of action that results in profound
lymphopaenia, opportunistic infections are rarely seen
and no excess association with malignancy has been iden-
tified. However, acquired autoimmune disease (AID) is a
common adverse event following treatment, necessitating
rigorous monitoring in order to facilitate prompt detection
and management. Despite this issue, a unique dosing
schedule and durability of effect make alemtuzumab a
welcome addition to currently available treatment options
for MS.
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Introduction
Multiple sclerosis (MS) is a common, inflammatory disease of
the central nervous system, responsible for substantial
morbidity in western populations [1]. The underlying pathol-
ogy is complex and remains poorly understood. However,
amongst a complex interplay of immunological factors, T
lymphocytes are known to occupy a central role in disease
pathogenesis [2, 3]. Over the last two decades, an increased
understanding in disease biology and genetic susceptibility
has contributed to the development of novel therapeutic inter-
ventions which are largely designed to target function and
migration of T lymphocytes [4].With a substantial therapeutic
armamentarium now available, it has become imperative to
understand the clinical effects of these interventions and their
place in treatment regimes.
Alemtuzumab, an anti-CD52monoclonal antibody, was first
proposed as a treatment for MS in the 1990s [5, 6]. Following
clinical trials demonstrating a dramatic effect on relapse rates,
in addition to a positive effect on longer term disability out-
comes [7–9], it has now been approved for use in 49 countries
worldwide [10]. Its primary indication is for active relapsing
disease, either as first- or second-line treatment, although in a
small number of countries has been restricted to patients who
have had an inadequate response to two or more established
disease-modifying therapies. As well as having an impressive
clinical effect across a number of end points including relapse
rate, brain atrophy and measures of disability, treatment with
alemtuzumab has also offered some fascinating insights [11,
12] into clinical aspects of MS and allowed a greater under-
standing of disease pathogenesis. Furthermore, as a result of the
now well-established side effect of disease-specific autoimmu-
nity, it has provided an unintended but intriguing window into
the origins of human autoimmune disease.
In this review article, we aim to summarise the mechanism
of action of alemtuzumab and key findings from clinical trials
as well as more recently published long-term follow-up data.
We will also outline the main side effects of this therapy and
offer practical points for its use in clinic practice.
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Mechanism of Action
Alemtuzumab is a humanised monoclonal antibody targeted
against the cell surface protein CD52 [13]. The function of
this molecule is largely unknown, although is thought to
contribute to T cell activation [14], migration [15] and the
induction of regulatory T cells [15]. CD52 is present pri-
marily on the cell surface of lymphocytes but also at lower
levels on monocytes, macrophages, eosinophils and NK
cells [16–18]. Epithelial cells of the epididymis, vas
deferens and seminal vesicle also express CD52 at low
levels [16–18]. However, of critical Importance, a lack of
CD52 expression on bone marrow-derived haematopoietic
precursors allows lymphocyte reconstitution following treat-
ment and return of immune competency [19].
Alemtuzumab treatment results in a rapid and pro-
found reduction in peripheral lymphocytes due to
antibody-dependent cell-mediated cytotoxicity [20],
complement-dependent cytolysis and induction of apo-
ptosis [21] with a subsequent beneficial reconstitution
of the immune system [22]. Repopulation occurs via
two mechanisms: proliferation of mature lymphocytes
that escape deletion (‘homeostatic proliferation’) and via
bone marrow/thymic repopulation (Fig. 1).
Following treatment, rates of lymphocyte recovery vary by
cell type, with B lymphocytes first to recover followed by
CD8+ and CD4+ T lymphocytes [23–25]. Although contro-
versial, the rate and pattern of lymphocyte reconstitution are
not currently thought to correlate with subsequent re-
emergence of disease activity [23, 26, 27]. As immune recon-
stitution becomes more established, regulatory CD4+ T cells
(Tregs) dominate the T cell population and are considered to
be one of the factors contributing to long-term efficacy rather
than this being solely a result of lymphodepletion [28–30]. In
particular, a recent study reporting results from the phase III
trials has demonstrated a significant increase in Treg cell per-
centage at 24 months after treatment [31]. An increased rep-
resentation of memory T lymphocytes is also observed [32],
although the impact of this phenomenon is less clear.
Furthermore, mRNA levels of pro-inflammatory cytokines
and anti-inflammatory cytokines are downregulated and up-
regulated, respectively, following treatment, which may also
contribute to the drug’s unique durability in MS [31].
The potential role of neutralising antibodies to
alemtuzumab (which have been identified following treat-
ment and become less frequent in subsequent courses) in
modifying efficacy remains unclear. However, levels can
be reduced by co-administration of SM3, a non-cell bind-
ing variant of alemtuzumab [33], which, whilst not cur-
rently available for routine clinical use, may offer a fu-
ture route for managing a subset of patients who fail
treatment because of the development of neutralising
antibodies.
Development of Alemtuzumab in the Treatment
of MS
Early Experience
Prior to its use as a therapy forMS, alemtuzumab was licensed
for fludarabine resistant chronic lymphocytic leukaemia in
addition to its application in organ transplantation and other
autoimmune disorders [34]. Early in the clinical development
programme for MS, alemtuzumab was used in patients with
advanced progressive disease. Although radiological out-
comes were encouraging, disability accumulation continued
with increased cerebral atrophy 7 years after treatment [5, 6,
11, 34]. In contrast, patients with relapsing disease experi-
enced a reduction in annualised relapse rates (ARR) and an
improvement in disability. This dichotomy of clinical out-
comes between patients treated at an earlier stage of disease
and those with progressive disease offered important insights
Fig. 1 Proposed mechanism of action of alemtuzumab. a Alemtuzumab
targets B and T lymphocytes by one of three mechanisms. 1
Complement-mediated cytolysis. 2 Antibody-dependent cytolysis. 3
Induction of apoptosis. b Lymphocyte repopulation occurs through either
1 production of new T and B lymphocytes or 2 through homeostatic
repopulation of surviving lymphocytes
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into disease pathogenesis and timing of interventions. Early
disease was concluded to be the result of a more active inflam-
matory demyelinating phase and followed by a later phase of
axonal degeneration and accumulation of disability.
Subsequent investigation therefore focused on the inflamma-
tory disease subtype characterised clinically by a relapse dom-
inant disease course, with two open-label trials in treatment-
naïve and treatment refractory patients showing encouraging
clinical outcomes [35, 36].
Clinical Trials (CAMMS223, CARE-MSI
and CARE-MSII)
One phase II (CAMMS223) [9] and two phase III (Comparison
of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis
(CARE-MS) I and II) [7, 8] clinical trials were undertaken
following these positive early experiences. CAMMS223 com-
pared low- and high-dose alemtuzumab against a high-dose
active comparator (subcutaneous interferon beta 1-a, Rebif®,
44 μg three times weekly) in patients with early, active,
relapsing-remitting MS [9]. CARE-MSI [7] and CARE-MSII
[8] investigated the use of alemtuzumab in treatment-naïve
patients and in patients previously on disease-modifying ther-
apy who had experienced an inadequate response (≥1 relapse),
respectively. As with the phase II study, interferon beta 1-a was
used as an active comparator. Inclusion criteria and clinical
outcomes for these trials are summarised in Table 1.
CAMMS223
Treatment-naïve patients (334) with a diagnosis of relapsing-
remitting MS (RRMS) were randomised to alemtuzumab
12 mg/day, alemtuzumab 24 mg/day or high-dose subcutane-
ous interferon beta 1-a three times weekly. Results from this
study were impressive both for clinical and radiological out-
comes. The pooled (12 and 24mg) alemtuzumab groups dem-
onstrated a reduction in ARR of 74 %, reduction in sustained
accumulation of disability (SAD; a ≥1-point increase in
Expanded Disability Status Score (EDSS) [39] from baseline
if baseline EDSS >0, or ≥1.5 point increase if baseline
EDSS = 0, persistent over a 6-month period) of 71 % and
improvement inmeanEDSS score of 0.39 points at 36months.
In contrast, patients treated with interferon beta 1-a experi-
enced a worsening of EDSS score of 0.38 points over the same
time period. Radiologically, reduction in brain volume was
significantly less in the pooled alemtuzumab treatment group.
Similarly, although reduction in lesion volume on T2-
weighted MRI was seen in both alemtuzumab and beta inter-
feron patients, this was more notable in the alemtuzumab
groups, with significance seen at 12 and 24 months; however,
at 36 months, this effect was not significant [9].
The cohort of patients involved in CAMMS223 continued
to demonstrate improvements in EDSS at 5 years of follow- Ta
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up, although the majority of this effect was in the first
36 months [40]. A post hoc analysis using a new disability
outcome, sustained reduction of disability (SRD, a reduction
from baseline of at least 1 EDSS point confirmed over
6 months for patients with a baseline EDSS ≥2.0), demonstrat-
ed more alemtuzumab-treated patients achieved this outcome
compared with interferon-treated patients [41].
CARE-MSI and CARE-MSII
In the phase III follow-up to CAMMS223, CARE-MSI and
CARE-MSII investigated alemtuzumab therapy in treatment-
naïve and treatment-experienced patients, respectively. These
studies were conducted over a 2-year period with the primary
endpoints of ARR and time to 6-month SAD [7, 8]. In CARE-
MSI, patients received alemtuzumab at a dose of 12 mg/day
[7]. In CARE-MSII alemtuzumab, patients were randomised
to a dose of either 12 or 24mg/day, although after 1 year of the
study, all patients received 12 mg [8]. Discontinuation of ran-
domization to the 24-mg/day group was undertaken because
of safety concerns following the reported case of ITP but also
to aid recruitment to the remaining study groups.
Once again, alemtuzumab demonstrated superiority to in-
terferon beta 1-a. Patients experienced a reduction of ARR in
CARE-MSI and CARE-MSII by 55 and 49%, respectively [7,
8]. EDSS score was also improved in the alemtuzumab groups
in both studies. Although this was significant in CARE-MSII
(improvement of 0.17 points on alemtuzumab vs. a worsening
of 0.24 in the interferon beta 1-a group), both groups experi-
enced an improvement in EDSS in CARE-MSI (improvement
of 0.14 points in both groups), which did not achieve signif-
icance [7, 8]. Similarly, in CARE-MSII, significantly fewer
patients had SAD (13 vs. 20 %) and more patients had SRD
(22 vs. 9 %) in the alemtuzumab group. Again, in contrast to
CARE-MSII, significance was not achieved in SAD in
CARE-MSI, although SRD was not measured [7, 8].
Interim data from the ongoing phase III extension study
have demonstrated marked durability over 5 years [42, 43].
For patients enrolled in CARE-MSI and CARE-MSII, the low
ARRwasmaintained in year 3 (0.19 and 0.22, respectively) to
year 5 (0.15 and 0.18). For years 0–5, 80% patients in CARE-
MSI and 75 % patients in CARE-MSII were free from 6-
month SAD. Impressively, 69 and 65 % patients, respectively,
had stable/improved EDSS scores and 33 and 43 % patients
experienced SRD in years 0–5 [42, 43]. It has been suggested
that the improvement in disability observed following treat-
ment might be as a result of increased lymphocytic delivery of
neurotrophins to the CNS aiding neuroprotection [44].
Radiological outcomes were also significantly better in the
alemtuzumab-treated patients compared with interferon beta
1-a. In particular, change in brain volume (BV), gadolinium-
enhancing lesions and patients with new or enlarging T2 hy-
perintense lesions on MRI were significantly better in the
alemtuzumab groups in both studies [7, 8]. In the recently
presented data from the extension study, these radiological
changes also appear to have durability after 5 years of fol-
low-up. Median rate of BV loss decreased progressively over
4 years in CARE-MSI and remained low in year 5 (year 1,
−0.59 %; year 2, −0.25 %; year 3, −0.19 %; year 4, −0.15 %;
year 5, −0.20 %). Similarly, median rate of BV loss progres-
sively slowed over 3 years in CARE-MS II and remained low
in years 4 and 5 (year 1, −0.48 %; year 2, −0.22 %; year 3,
−0.10 %; year 4, −0.19 %; year 5, −0.07 %). Strikingly, the
majority of patients (68 % in CARE-MSI and 60 % in CARE-
MSII) had not received further courses of alemtuzumab treat-
ment since month 12 [45]. Durability of MRI outcomes has
also been shown in the extension study with respect to gado-
linium (Gd)-enhancing lesions, new/enlarging T2 or new T1
lesions. In years 3, 4 and 5 after initial treatment, the propor-
tion of patients free of the aforementioned measures was sim-
ilar to those in year 2 (i.e. the end of the original phase III
studies). In addition, most patients were free of MRI activity
in each of years 3, 4 and 5 [46, 47].
Open-Label Cohorts
In recent years, long-term follow-up data from open-label co-
horts have also been available (Table 2). After a median 7-year
follow-up of 87 patients with RRMS from two previous stud-
ies, 6-month SAD and SRD were observed in 32.2 and
43.5 %, respectively, in patients treated by a group in
Cambridge, UK. Area under the curve analysis demonstrated
an overall improvement or stabilisation of disability in 59.8 %
patients. Consistent with previous studies, ARRwas drastical-
ly reduced by 91 %. Mean EDSS reduction was 0.2 points
[48]. Further data from this cohort has recently been present-
ed: after a median time of 10.1 years, 45 % patients with
RRMS remained relapse-free. Forty-one patients (48 %) re-
quired the standard two cycles of alemtuzumab, whilst re-
lapses triggered re-treatment to a total of three cycles (in 33
patients (38 %)), four cycles (in nine patients (10 %)) and five
cycles (in three patients (3 %)). Disability measured by EDSS
remained largely unchanged. Conversely, for 36 patients with
secondary progressive disease (with a median follow-up of
19.8 years), the median EDSS significantly increased from 6
to 8.75 [50].
In our own cohort encompassing 100 patients treated in
Bristol and South Wales, UK, we observed similar reduc-
tion in ARR of 90 %. Forty patients underwent at least
one additional course of treatment triggered by clinical or
radiological changes. Although a reduction in mean EDSS
was not observed, an increase of 0.14 EDSS points might
still be considered a striking outcome since treatment had
been reserved for patients with the most aggressive forms
of disease [49].
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Adverse Events
The main adverse events following alemtuzumab include
well-recognised infusion reactions, infections and acquired
autoimmune disease including thyroid disorders, idiopathic
thrombocytopaenic purpura (ITP) and immune-mediated ne-
phropathies. Other rarely occurring autoimmune disease ob-
served in the CARE-MS trials included neutropaenia,
haemolytic anaemia, agranulocytosis and pancytopenia [7, 8].
Autoimmune Disease
A unique observation in the use of alemtuzumab in MS is the
occurrence of acquired autoimmune disease (AID), which is
not observed in other conditions treated with this drug [51]. A
range of autoimmune conditions has been described and in our
own long-term follow-up cohort amounted to 47% of patients
[49]. Autoimmune disease of the thyroid gland is the most
commonly occurring condition, with others including ITP
and anti-glomerular basement membrane (anti-GBM) disease
seen less frequently [7–9]. This development of novel auto-
immunity is currently the focus of active research, offering a
window into the genesis of human autoimmune disease.
Whilst the underlying mechanism is still not fully understood,
it is thought to occur as a result of subsequent homeostatic T
cell proliferation following lymphodepletion [52], and where
homeostatic proliferation predominates over thymic reconsti-
tution, autoimmune disease is more likely [52]. Of interest,
thyroid AID following alemtuzumab treatment is not seen in
patients treated with B cell chronic lymphocytic leukaemia
despite being given at higher doses suggesting a disease-
specific phenomenon [51].
Early experience suggested an occurrence of thyroid AID
in approximately 30 % of patients [34, 53]. Similar rates were
seen in CAMMS223, CARE-MSI and CARE-MSII at 23, 18
and 16 %, respectively [7–9]. A large multi-centre cohort sub-
sequently demonstrated thyroid AID rates of 17 % [54]. In
recently published long-term follow-up cohorts, total AID
specific to the thyroid has been shown to occur at a higher
rate and probably reflects longer follow-up. In our own multi-
centre cohort, 47 % developed AID of which 35 % were
thyroid [49]. Similarly, in the Cambridge cohort, 48% patients
experienced any AID with thyroid AID occurring in 41 % of
patients [48]. The incidence of thyroid AID appears to be
greatest in the first 3 years following the initial treatment
course [42, 43, 48, 49] and responds to conventional therapies
and management [51]. Importantly, the risk of developing
AID has been shown to be unaffected by the cumulative dose,
dosage interval or dosage frequency [48, 54].
A variety of other autoimmune conditions have also been
documented [49]. The most significant of which is ITP.
CAMMS223 was suspended after three patients developed
ITP with one patient dying of an intracerebral haemorrhage
before a diagnosis could be made. During the suspension pe-
riod, three further patients were diagnosed. In the subsequent
phase III and open-label cohorts, the rate of ITP has been
shown to be between 1 and 3 % [7, 8, 48, 49, 54]. ITP asso-
ciated with alemtuzumab therapy is thought to be
characterised by delayed presentation after drug exposure, re-
sponsiveness to conventional therapies (corticosteroids, intra-
venous IgG, anti-Rh(D), platelet transfusion, rituximab) and
prolonged remission [55].
Although even less common, renal disease has been report-
ed in four patients within the clinical trials—one case of anti-
glomerular basement membrane (anti-GBM) disease and
three cases of membranous nephropathy (one of which also
had low-level anti-GBM antibodies). Each patient responded
to promptmedical treatment with plasmapharesis, steroids and
cyclophosphamide and diuretics for anti-GBM disease and
membranous nephropathy, respectively [56]. Three further pa-
tients treated outside of the clinical trials have also developed
anti-GBM disease. Despite aggressive immunotherapy, two
patients became dialysis-dependent and ultimately required
renal transplantation, whilst the other although not requiring
renal replacement has end-stage renal disease (A Coles, per-
sonal communication). Higher levels of Il-21 have been
Table 2 Clinical outcomes and
adverse events of alemtuzumab-
treated patients in two open-label
cohorts [37]
Cambridge open-label long-term follow-up co-
hort [48]
Cardiff regional cohort
[49]
Patient number 87 100
Follow-up (years) 7 (median) 6.1 (mean)
Relapse rate reduction from
baseline
91 % 90 %
% patients with 6-month SAD 32 % 27 %
Change in mean EDSS from
baseline
−0.2 +0.14
Autoimmunity
Thyroid 41 % 35 %
ITP 3.4 % 3 %
Goodpasture’s syndrome 1 % 0 %
SAD sustained accumulation of disability, EDSS expanded disability status score, ITP Idiopathic
thrombocytopaenic purpura
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shown to be associated with developing autoimmune disease
post-alemtuzumab [57], but a test for this has so far not
reached standard clinical practice [58].
Infections
For a therapy whose main biological effect is lymphopaenia,
rates of serious opportunistic infections might reasonably be
expected to be high. In the CARE-MS studies, mild to mod-
erate infections were seen in 67–77 % patients receiving the
12-mg dose of alemtuzumab (vs. 45 and 66 % of those receiv-
ing interferon β1a). Upper respiratory tract, urinary tract and
herpes simplex and zoster virus infections remain the most
commonly observed [7, 8, 48, 49]. Infections attributable to
immunosuppression in open-label studies include spirochaetal
gingivitis, pyogenic granuloma and listeria meningitis. In ad-
dition, one further case of listeria meningitis was observed in
the CAMMS223 study [9] with two more cases also recently
being reported [59].
Although it is clear that vigilance needs to be maintained
for opportunistic infections which can be severe, the relatively
low frequency given the mode of action of alemtuzumab is
intriguing and likely to represent a relative sparing of cells of
the innate immune system in addition to haemopoetic precur-
sor cells in the bonemarrow and thymus. Subsequent lympho-
cyte repopulation following treatment also aids immune sur-
veillance, and murine models have demonstrated that the
function of the remaining lymphocytes following treatment
is unimpeded [60].
Malignancy
Although malignancies were seen in the clinical trials, the stud-
ies were not powered to detect changes between the groups. In
CARE-MSI and CARE-MSII, malignancies were observed in
0.5 vs. 0 % and 0.6 vs. 1.5 % in the 12-mg alemtuzumab and
interferon beta-1a-treated patients, respectively [7, 8]. Of 1486
total patients treated with alemtuzumab in the clinical develop-
ment programme, 29 (2 %) have developed neoplastic disease.
Thyroid cancer accounted for six cases, which may relate to the
increased thyroid surveillance undertaken in treated patients
[61, 62]. All were stage 1 papillary type carcinomas and dis-
covered 10–41 months after last dose. One patient had a
preexisting lymph node at baseline that was subsequently
found to contain papillary thyroid cancer [62]. Basal cell carci-
noma (six patients), breast cancer (five) and malignant melano-
ma (four) occurred at a frequency >1 %.
Outside of clinical trials, one further case of papillary thy-
roid carcinoma [63], one case of malignant melanoma [64]
and one case of Castleman’s disease (a prelymphomatous con-
dition) [38] have separately been reported. In addition, in our
recent long-term follow-up cohort of 100 patients, 10 patients
developed malignant/pre-malignant conditions. Three patients
had monoclonal gammopathy of uncertain significance
(MGUS), one of which was also diagnosed with a meningio-
ma, two basal cell carcinomas and five patients had cervical
dysplasia. Despite the theoretical risk of cervical malignancy
following T lymphocyte depletion, there is currently no defin-
itive available evidence that individual risk is increased com-
pared to that of the background population. Despite this, it is
recommended that female patients undergo annual cervical
screening following treatment [65]. It should be noted that
the risk of malignancy following immunosuppression may
take many years to manifest and therefore detailed post-
marketing surveillance will be essential to better define long-
term risks.
Pregnancy
Alemtuzumab may cross the placental barrier and therefore
potentially produce harmful effects on the foetus. In animal
studies, reproductive toxicity has been demonstrated although
data in humans is lacking. It is unknown therefore whether
alemtuzumab administration effects reproductive capacity or
teratogenicity [65]. Because of the theoretical risk of pregnan-
cy adverse events, the parent company recommends effective
contraception during and for 4 months following treatment.
The most recently reported data of 1486 patients (64.8 % fe-
male) treated in the clinical trials reveals 179 pregnancies
occurring in 131 patients. Of completed pregnancies, 104
(66 %) were live births. No congenital abnormalities have
been observed in delivered infants. Excluding pregnancies
with unknown outcomes, there were 36 (21 %) spontaneous
abortions, 16 (9 %) elective abortions and 1 (0.6 %) stillbirth.
Rates of spontaneous abortions are similar to those in the
general population [66]. Although CD52 is expressed in the
epididymis, seminal vesicle, sperm and seminal fluid, suggest-
ing a theoretical risk of reduced male fertility, a small study
has not demonstrated any effects on sperm motility, morphol-
ogy or count [67].
Practical Considerations
In the context of MS treatment, alemtuzumab is given intra-
venously at a dose of 12 mg/day for 5 consecutive days,
followed 12 months later by a further 3-day course.
Cytokine release following alemtuzumab treatment is now
well recognised with a rise in TNF-α, IL-6 and IFN-γ accom-
panying lymphodepletion [12]. This phenomenon is thought
to explain the transient worsening of symptoms experienced
by patients treated at an early stage of the drugs use. This is
thought to occur because of a direct action on partially
demyelinated pathways and is mitigated by the use of con-
comitant intravenous methylprednisoloine for the first 3 days
of any treatment cycle [12]. Other common side effects seen
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during infusion include headaches, rigors, pyrexia and rash.
As such, anti-pyretics and anti-histamines are given on an ‘as
required’ basis for symptomatic control. In the clinical trials,
infusion reactions occurred in ≥90 % patients [7–9].
Because of the relative increased incidence of herpes infec-
tions following treatment, administration of oral acyclovir
(200 mg BD) is recommended during and for 1 month follow-
ing treatment [65], which has been demonstrated to reduce the
risk of herpetic virus infection [68]. In addition, patients with-
out a history of chickenpox or vaccination against varicella
zoster virus (VZV) should be checked for anti-VZVantibodies
and be considered for VZV vaccination >6 weeks prior to
treatment [65]. Although a small study has demonstrated that
humoral responses after alemtuzumab treatment to common
inactive vaccines are still effective [69], there is no data avail-
able for the safety of live vaccination following treatment [65].
It is therefore recommended that patients should complete
local immunisation requirements at >6 weeks before com-
mencing treatment and do not receive live vaccinations fol-
lowing treatment [65]. Patients are also given dietary advice to
avoid foodstuffs that may contain listeria including soft
cheeses, pates and smoked seafood.
With a high incidence of adverse autoimmune events, a
rigorous safety-monitoring programme is required (Table 3).
Prior to treatment initiation, complete blood count, serum cre-
atinine, thyroid function and urinalysis should be performed
and on a monthly basis thereafter or three monthly for thyroid
function tests. Monitoring should continue for 48 months fol-
lowing the last treatment course [65], and any abnormality in
monitoring outcomes should prompt urgent referral to the ap-
propriate specialty for management. Our own experience is
that patient education with regards to identifying early symp-
toms of AIDs is of paramount importance in order that poten-
tially serious conditions can be promptly identified. Because
of the theoretical increased risk of cervical malignancy due to
human papillomavirus (HPV), patients are also recommended
to undergo cervical screening prior to treatment initiation and
at annual intervals thereafter [65].
Within the clinical trials, patients were retreated with a
further 3-day course of alemtuzumab on the basis of ≥1 pro-
tocol defined relapse or ≥2 new or Gd-enhancing or enlarging
brain or spinal cord lesions. Recently, presented data has
shown that 68 and 50% of patients have received no treatment
since month 12 of CARE-MSI and CARE-MSII, respectively
[42, 43]. In our practice, patients have been retreated either for
(i) clinical relapse only, (ii) new radiological lesions (with or
without enhancement), (iii) clinical relapse and new radiolog-
ical lesions, (iv) worsening disability and new radiological
lesions or (v) worsening disability without change in EDSS
[49]. Twenty-eight percent of patients have received three
treatments, 11 % four treatments and one patient five treat-
ments [49]. However, there is no current consensus on
retreatment thresholds and further trials are needed for
clarification.
Conclusions
With options for disease-modifying therapies (DMTs) in MS
continuing to expand, the question of when and how best to
utilise the available intervention is becoming ever more rele-
vant [70]. Alemtuzumab has been shown to have a dramatic
effect on relapse rates in patients with MS as well as a positive
effect on disability and radiological outcomes. However, it
remains unclear whether alemtuzumab should predominantly
be reserved for patients who fail standard DMTs such is the
case in the USA or as a first-line option to treat selected patient
sub-groups during a putative ‘window of therapeutic opportu-
nity’. So-called escalation and induction regimes are the focus
of substantial recent conjecture with clinical trials urgently
needed to help resolve this issue. As well as efficacy, the
long-term impact of drugs that employ different modes of
immunomodulation is unknown and will be an important fu-
ture consideration for patients and clinicians.
Despite the relatively high-risk of AID following
alemtuzumab, it offers an attractive therapeutic option as a
result of a unique dosing regimen, efficacy and durability of
treatment as well as its ability to be incorporated safely within
family planning. However, a rigorous monitoring programme
together with effective patient education is essential to facili-
tate early identification and management of AIDs. As a result,
it should be acknowledged that capacity for adherence to
monitoring requirements might affect patient selection.
Finally, as with all relatively novel treatments, there remains
a need for continuing clinical vigilance for adverse events in
clinical practice as well as long-term safety studies.
Table 3 Monitoring guidelines [37]
Monitoring test Monitoring interval Duration
Complete blood count Prior to treatment initiation and at monthly intervals thereafter For 48 months following last treatment course
Serum creatinine Prior to treatment initiation and at monthly intervals thereafter For 48 months following last treatment course
Urinalysis with microscopy Prior to treatment initiation and at monthly intervals thereafter For 48 months following last treatment course
Thyroid function tests Prior to treatment initiation and every 3 months thereafter For 48 months following last treatment course
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